Characteristics of health-related quality of life and related factors in patients with brain tumors treated with rehabilitation therapy

Watanabe, Takahiro; Noto, Shinichi; Natsumeda, Manabu; Kimura, Shinji; Tabata, Satoshi; Ikarashi, Fumie; Takano, Mayuko; Tsukamoto, Yoshihiro; Oishi, Makoto

doi:10.1186/s41687-022-00499-y

Journal of Patient-Reported Outcomes

Table 2 Comparison of disease-specific HQOL scale in tumor classification

From: Characteristics of health-related quality of life and related factors in patients with brain tumors treated with rehabilitation therapy

	All patients	Glioblastoma	WHO grade III	PCNSL	MBT	WHO grade I	p value
	n = 76	n = 21	n = 10	n = 10	n = 9	n = 26
	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD
QLQ-C30 functional domains^a
Physical functioning	67.5 ± 27.7	61.0 ± 31.6	61.3 ± 35.7	69.3 ± 25.8	70.4 ± 25.6	73.6 ± 23.5	0.612
Role functioning	56.4 ± 33.0	52.4 ± 28.5	53.3 ± 44.3	50.0 ± 31.4	64.8 ± 26.9	60.3 ± 35.3	0.75
Cognitive functioning	68.0 ± 25.2	63.5 ± 19.4	63.3 ± 35.8	61.7 ± 29.4	68.5 ± 26.9	75.6 ± 22.2	0.373
Emotional functioning	78.4 ± 16.1	68.7 ± 19.3	75.8 ± 12.1	82.5 ± 9.2	77.8 ± 20.4	85.9 ± 10.7	0.015
Social functioning	66.9 ± 29.4	57.1 ± 28.2	60.0 ± 28.5	76.7 ± 23.8	68.5 ± 30.6	73.1 ± 31.3	0.277
Global Health Status	52.3 ± 23.8	46.0 ± 24.2	48.3 ± 15.6	50.0 ± 27.5	57.4 ± 34.0	58.0 ± 20.5	0.422
QLQ-C30 symptom domains^a
Nausea and vomiting	5.7 ± 14.5	3.2 ± 6.7	18.3 ± 30.9	5.0 ± 11.2	5.6 ± 8.3	3.2 ± 10.6	0.605
Fatigue	40.3 ± 21.1	43.4 ± 12.6	46.7 ± 28.6	44.4 ± 18.1	39.5 ± 29.5	34.2 ± 21.3	0.448
Dyspnea	18.9 ± 27.9	19.0 ± 30.9	13.3 ± 23.3	26.7 ± 34.4	22.2 ± 23.6	16.7 ± 27.1	0.858
Pain	21.1 ± 21.3	30.2 ± 18.7	13.3 ± 17.2	18.3 ± 21.4	20.4 ± 33.1	17.9 ± 18.8	0.157
Insomnia	29.8 ± 29.1	33.3 ± 33.3	26.7 ± 34.4	36.7 ± 36.7	33.3 ± 16.7	24.4 ± 24.1	0.698
Appetite loss	21.1 ± 26.6	17.5 ± 22.7	20.0 ± 28.1	20.0 ± 23.3	40.7 ± 40.1	17.9 ± 23.5	0.631
Constipation	28.5 ± 29.2	33.3 ± 29.8	30.0 ± 33.1	30.0 ± 29.2	33.3 ± 33.3	21.8 ± 26.6	0.697
Diarrhea	10.1 ± 16.3	11.1 ± 16.1	3.3 ± 10.5	10.0 ± 16.1	22.2 ± 23.6	7.7 ± 14.3	0.253
Financial difficulties	33.3 ± 31.3	55.6 ± 28.5	26.7 ± 34.4	36.7 ± 33.1	29.6 ± 26.1	17.9 ± 23.5	0.002
BN20 symptom domains^b
Future uncertainty	34.3 ± 24.3	47.6 ± 24.0	36.7 ± 23.6	37.5 ± 26.7	32.4 ± 23.0	22.1 ± 19.1	0.014
Visual disorder	17.5 ± 28.3	10.1 ± 17.9	15.6 ± 32.8	15.6 ± 30.6	21.0 ± 34.0	23.9 ± 30.9	0.459
Motor dysfunction	23.4 ± 24.2	33.3 ± 27.2	28.9 ± 32.4	20.0 ± 30.5	17.3 ± 21.6	16.7 ± 11.9	0.164
Communication deficit	17.8 ± 22.4	22.8 ± 26.2	12.2 ± 15.2	10.0 ± 11.0	35.8 ± 31.3	12.8 ± 18.0	0.135
Headache	22.8 ± 23.9	19.0 ± 19.9	20.0 ± 23.3	16.7 ± 23.6	18.5 ± 17.6	30.8 ± 28.2	0.48
Seizure	1.3 ± 6.5	1.6 ± 7.3	6.7 ± 14.1	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.068
Drowsiness	33.8 ± 28.5	36.5 ± 31.5	53.3 ± 28.1	26.7 ± 26.3	40.7 ± 36.4	24.4 ± 20.1	0.071
Hair loss	25.0 ± 30.9	34.9 ± 37.2	36.7 ± 33.1	23.3 ± 31.6	29.6 ± 30.9	11.5 ± 18.7	0.051
Itchy skin	18.0 ± 19.2	27.0 ± 22.7	20.0 ± 17.2	16.7 ± 17.6	18.5 ± 17.6	10.3 ± 15.7	0.107
Weakness of legs	40.8 ± 30.1	44.4 ± 26.5	46.7 ± 32.2	46.7 ± 32.2	44.4 ± 33.3	32.0 ± 30.5	0.558
Loss of bladder control	14.5 ± 23.9	14.3 ± 27.0	10.0 ± 16.1	13.3 ± 23.3	22.2 ± 23.6	14.1 ± 25.3	0.806

SD Standard deviation, PCNSL Primary central nervous system lymphoma, MBT Metastatic brain tumor
^aIn EORTC QLQ-C30, functional domains—higher scores are better; symptom domains—lower scores are better
^bIn EORTC BN20 symptom domains, lower scores are better
P value < 0.05 were written in boldface

Back to article page